Aspira Women's Health Providing A Downward Revision Of The 2024 Cash Used In Operations Guidance During Q2 2024 Earnings Call

6/13/24 8:04:47 AM ET

$AWH

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $AWH alert in real time by email

Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January

Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite

Cash used in operations guidance for 2024 expected to be lowered

AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024.

Get the next $AWH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AWH

Date	Price Target	Rating	Analyst
1/12/2022	$4.00	Overweight	Cantor Fitzgerald

More analyst ratings

$AWH
Financials

Live finance-specific insights

Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results
Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import
11/14/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R
11/4/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE A replay of the webcast will also be
7/31/24 4:05:00 PM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of
9/5/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors
AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past
7/29/24 9:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Aspira Women's Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company's product development team following the departure of Dr. Jody Berry AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President
3/18/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results
Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import
11/14/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC ("BioReference"), a wholly-owned subsidiary of OPKO Health Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira's complete OvaSuite portfolio, including OvaWa
11/7/24 8:00:00 AM ET
$AWH
$OPK
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biotechnology: Pharmaceutical Preparations
Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R
11/4/24 8:00:00 AM ET
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Aspira Women's Health Providing A Downward Revision Of The 2024 Cash Used In Operations Guidance During Q2 2024 Earnings Call

Chat with this insight

Recent Analyst Ratings for $AWH

$AWH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

Truist Securities initiated coverage on Aspira Womens Health with a new price target

Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

$AWH Financials

Live finance-specific insights

Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

$AWH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Director Ragard John Phillip converted options into 4,844 shares, increasing direct ownership by 4% to 120,203 units (SEC Form 4)

SEC Form 4 filed by Interim CFO Kallassy John A

SEC Form 4 filed by President Milligan Sandra

$AWH SEC Filings

SEC Form 10-Q filed by Aspira Women's Health Inc.

SEC Form NT 10-Q filed by Aspira Women's Health Inc.

Aspira Women's Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$AWH Leadership Updates

Live Leadership Updates

$AWH Large Ownership Changes

This live feed shows all institutional transactions in real time.

$AWH Market Insights

Live Market Insights

$AWH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$AWH Press Releases

Fastest customizable press release news feed in the world

Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

Aspira Women's Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

SEC Form SC 13G filed by Aspira Women's Health Inc.

Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

Aspira Women's Health Inc Files For Offering Of Up To 2.5M Shares By The Selling Stockholders

Aspira Women's Health shares are trading higher after the company announced that preliminary OvaWatch volume during Q2 2024 grew 24% quarter-over-quarter to 1,307 units.

Aspira Women's Health Announces Preliminary OvaWatch Volume During Q2 2024 Grew 24% QoQ To 1,307 Units; Preliminary OvaSuite Volume During Q2 2024 Grew 11% QoQ To 6,471 Units

Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Recent Analyst Ratings for
$AWH

$AWH
Analyst Ratings

$AWH
Financials

$AWH
Insider Trading

$AWH
SEC Filings

$AWH
Leadership Updates

$AWH
Large Ownership Changes

$AWH
Market Insights

$AWH
Insider Purchases

$AWH
Press Releases